Antonio Clemente1,2, Luca Cavagnaro3, Antonio Russo4,5, Francesco Chiarlone3, Alessandro Massè6,7, Giorgio Burastero8. 1. Department of Orthopedics and Traumatology, C.T.O. Hospital, via G. Zuretti 29, 10126, Turin, Italy. antonioclemente.ort@gmail.com. 2. Department of Surgical Science (DSC) University of Turin, C.so Dogliotti 14, 10126, Turin, Italy. antonioclemente.ort@gmail.com. 3. Joint Arthroplasty Unit, Orthopedic and Traumatology 2, Santa Corona Hospital, Viale XXV Aprile 38, Pietra Ligure, Italy. 4. Orthopaedic Clinic, San Martino Hospital, Largo R. Benzi 10, 16132, Genoa, Italy. 5. University of Genoa, Genoa, Italy. 6. Department of Orthopedics and Traumatology, C.T.O. Hospital, via G. Zuretti 29, 10126, Turin, Italy. 7. Department of Surgical Science (DSC) University of Turin, C.so Dogliotti 14, 10126, Turin, Italy. 8. Prosthetic Surgery Centre, Galeazzi Orthopedic Institute, via R. Galeazzi 4, 20161, Milan, Italy.
Abstract
PURPOSE: The purposes of this study were to determine demographics and characteristics of patients who underwent spacer exchange for persistent infection in the setting of two-stage arthroplasty for periprosthetic joint infection, to describe the microbiology of pathogens involved, to analyze survivorship free from infection in these patients. METHODS: The institutional prospectively collected database was reviewed to enroll patients with minimum 2 years follow-up. Patients who underwent two-stage procedure for septic arthritis were excluded, as were patients who had spacer fracture or dislocation. RESULTS: A total of 34 patients (41 procedures) were included. Mean age was 65.0 ± 12.8 years. Mean follow-up was 53.4 ± 24.8 months. Mean number of previous procedures was 3.6 ± 1.2. A total of 27 (79.4%) patients underwent final reimplantation. The most frequently isolated pathogen in spacer exchange was Staphylococcus epidermidis (10 cases, 28.6%). Polymicrobial cultures were obtained from 9 (25.71%) patients, 10 (28.6%) presented culture-negative infections. A total of 11 (32.4%) resistant pathogens were isolated, and 16 (47.0%) difficult to treat pathogens were detected. Eradication rate was 78.8%. Overall survivorship of implants after final reimplantation was 72.8% at 51.8 months. CONCLUSION: Surgeons should be aware that subjects necessitating spacer exchange often present multiple comorbidities, previous staged revision failures, soft-tissue impairment and difficult to treat infection. In these patients, spacer exchange provides good clinical results and infection eradication, preventing arthrodesis or amputation.
PURPOSE: The purposes of this study were to determine demographics and characteristics of patients who underwent spacer exchange for persistent infection in the setting of two-stage arthroplasty for periprosthetic joint infection, to describe the microbiology of pathogens involved, to analyze survivorship free from infection in these patients. METHODS: The institutional prospectively collected database was reviewed to enroll patients with minimum 2 years follow-up. Patients who underwent two-stage procedure for septic arthritis were excluded, as were patients who had spacer fracture or dislocation. RESULTS: A total of 34 patients (41 procedures) were included. Mean age was 65.0 ± 12.8 years. Mean follow-up was 53.4 ± 24.8 months. Mean number of previous procedures was 3.6 ± 1.2. A total of 27 (79.4%) patients underwent final reimplantation. The most frequently isolated pathogen in spacer exchange was Staphylococcus epidermidis (10 cases, 28.6%). Polymicrobial cultures were obtained from 9 (25.71%) patients, 10 (28.6%) presented culture-negative infections. A total of 11 (32.4%) resistant pathogens were isolated, and 16 (47.0%) difficult to treat pathogens were detected. Eradication rate was 78.8%. Overall survivorship of implants after final reimplantation was 72.8% at 51.8 months. CONCLUSION: Surgeons should be aware that subjects necessitating spacer exchange often present multiple comorbidities, previous staged revision failures, soft-tissue impairment and difficult to treat infection. In these patients, spacer exchange provides good clinical results and infection eradication, preventing arthrodesis or amputation.
Authors: Vinod H Thourani; Susheel Kodali; Raj R Makkar; Howard C Herrmann; Mathew Williams; Vasilis Babaliaros; Richard Smalling; Scott Lim; S Chris Malaisrie; Samir Kapadia; Wilson Y Szeto; Kevin L Greason; Dean Kereiakes; Gorav Ailawadi; Brian K Whisenant; Chandan Devireddy; Jonathon Leipsic; Rebecca T Hahn; Philippe Pibarot; Neil J Weissman; Wael A Jaber; David J Cohen; Rakesh Suri; E Murat Tuzcu; Lars G Svensson; John G Webb; Jeffrey W Moses; Michael J Mack; D Craig Miller; Craig R Smith; Maria C Alu; Rupa Parvataneni; Ralph B D'Agostino; Martin B Leon Journal: Lancet Date: 2016-04-03 Impact factor: 79.321
Authors: Giorgio Burastero; Marco Basso; Giuliana Carrega; Luca Cavagnaro; Francesco Chiarlone; Carlo Salomone; Gabriele Papa; Lamberto Felli Journal: Hip Int Date: 2016-11-25 Impact factor: 2.135
Authors: Matthew P Siljander; Kade S McQuivey; Adam M Fahs; Lisa A Galasso; Kevin J Serdahely; Mark S Karadsheh Journal: J Arthroplasty Date: 2018-07-03 Impact factor: 4.757
Authors: Luz Kelly Anzola; Andor W J M Glaudemans; Rudi A J O Dierckx; F Andres Martinez; Sergio Moreno; Alberto Signore Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-28 Impact factor: 9.236